



C. DIFFICILE INFECTION (CDI)—

A vicious cycle of recurrence that results in a significant burden^{1,2}

APPROXIMATELY HALF A MILLION CDI CASES
IN THE UNITED STATES ANNUALLY^{2,3}



RECURRENT CDI (rCDI) AFFECTS PATIENT QUALITY OF LIFE
AND HOSPITAL QUALITY METRICS AND REIMBURSEMENT



BREAK THE CYCLE



LEARN MORE ABOUT BREAKING THE
CYCLE OF C. DIFF RECURRENCE AT
WWW.POWEROFMICROBIOME.COM

FERRING

PHARMACEUTICALS

US-MBIO-2000005 July 2020
©2020 Ferring B.V. All rights reserved.

Antibiotics are the standard of care for the treatment of *C. diff* and effective for some. However, their use has been shown to disrupt the ecology of the gut microbiome and are a predominant risk factor for CDI recurrence.¹¹

References: 1. Centers for Disease Control and Prevention. <https://www.cdc.gov/drugresistance/pdf/threats-report/clostridioides-difficile-508.pdf>. Accessed June 24, 2020. 2. Feuerstadt P, et al. *J Med Econ*. 2020;23(6):603-609. 3. Lessa FC, et al. *N Engl J Med*. 2015;372(9):825-834. 4. Sandhu A, et al. [published online May 22, 2020]. *Emerg Infect Dis*. 2020;26(9):10.3201/eid2609.202126. doi:10.3201/eid2609.202126. 5. Scott TA, et al. AGA Abstracts. 2020;158(6)(suppl 1):s976. 6. Unni S, et al. Presented at AMCP 2020. April 21-24, 2020; Houston, Texas. 7. Riddle DJ, Dubberke ER. *Infect Dis Clin North Am*. 2009;23(3):727-743. 8. Rodrigues R, et al. *Infect Control Hosp Epidemiol*. 2017;38(2):196-202. 9. Unni S, et al. *JMCP* 2020;26(4a):s7. 10. Zilberberg MD, et al. *Medicine*. 2018;97(36):e12212. doi:10.1097/MD.00000000000012212. 11. McDonald LC, et al. *Clin Infect Dis*. 2018;66(7):e1-e48.